Laboratory monitoring of antifungal chemotherapy

The Lancet

Volumn 337, Issue 8757, 1991, Pages 1577-1580

  British Society For Antimicrobial Chemotherapy Working Party, ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; KETOCONAZOLE;

BLOOD LEVEL; DRUG SCREENING; HUMAN; LABORATORY; MINIMUM INHIBITORY CONCENTRATION; MYCOSIS; NONHUMAN; PATIENT MONITORING; PRIORITY JOURNAL; REVIEW;

ADULT; AMPHOTERICIN B; ANTIFUNGAL AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; FLUCONAZOLE; FLUCYTOSINE; HUMAN; IMMUNODIFFUSION; ITRACONAZOLE; KETOCONAZOLE; MICROBIAL SENSITIVITY TESTS; MYCOSES;

EID: 0025851865     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/0140-6736(91)93270-J     Document Type: Article

References (27)

1. Disk agar diffusion susceptibility testing of yeasts
2. Laboratory tests for the activity of imidazole and triazole antifungal agents in vitro
3. The maintenance and preservation of fungi
4. Results of a survey of antifungal susceptibility tests in the United States and interlaboratory comparison of broth dilution testing of flucytosine and amphotericin B
5. Effect of medium composition on results of macrobroth dilution antifungal susceptibility testing of yeasts
6. Amphotericin B-resistant yeast infection in severely immunocompromised patients
7. Isolation and characterization of a polyene-resistant variant of Candida tropicalis
8. Candida lusitaniae: frequency of recovery, colonization, infection, and amphotericin B resistance
9. Visceral fungal infections due to Petriellidium boydii (Allescheria boydii). In vitro drug sensitivity studies
10. Trichosporon beigelii, an emerging pathogen resistant to amphotericin B
11. Resistance to systemic antifungal agents
12. Antifungal activity of 5-fluorocytosine as measured by disc diffusion susceptibility testing
13. Correlation of in vitro susceptibility tests results with in vivo response: flucytosine therapy in a systemic candidiasis model
14. Laboratory methods for flucytosinc (5-fluorocytosine)
15. Long-term therapy of chronic mucocutaneous candidiasis with ketoconazole: experience with twenty-one patients
16. Modified response to ketoconazole of Candida albicans from a treatment failure
17. Azole resistance in Candida albicans
18. Gastropathy and ketoconazole malabsorption in the acquired immunodeficiency syndrome
19. The pharmacokinetics of ketoconazole in severely immunocompromised patients
20. Fluconazole resistance in Candida glabrata
21. In vitro studies with R51,211 (Itraconazole)
22. Comparison of high performance liquid chromatographic and microbiological methods for determination of itraconazole
23. The clinical pharmacokinetics of itraconazole: an overview
24. Oral itraconazole therapy of cryptococcal meningitis and cryptococcosis in patients with AIDS
25. Antifungal prophylaxis with itraconazole in prolonged neutropenia: correlation with plasma levels
26. Treatment of invasive aspergillosis with itraconazole
27. Pulmonary aspergillosis in the acquired immunodeficiency syndrome